Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AU565 | HER2amp | Luminal | Mebendazole | 0.107 | uM | 13030.174 | 0.9229 | 0.8222 | 0.8615 | |||
| SUM225CWN | HER2amp | Basal A | Ispinesib | KSP | Kinesin | 33.3 | uM | 7534.067 | 0.0004 | -0.9982 | 1.1276 | |
| SK-BR-3 | HER2amp | Luminal | Triciribine | AKT | AKT | 0.0107 | uM | 7526.074 | 0.8456 | 0.8068 | 1.6506 | |
| AU565 | HER2amp | Luminal | GSK1838705A | IGF1R | RTK | 0.533 | uM | 5900.098 | 0.9577 | 0.9627 | 2.2937 | |
| BT-474 | HER2amp | Luminal | L-779450 | BRAF | MAPK | 2 | uM | 12178.161 | 0.9731 | 0.9069 | 0.5721 | |
| UACC-812 | HER2amp | Luminal | ICRF-193 | TOP2 | TOP | 0.0107 | uM | 10580.139 | 1.0051 | 1.0108 | 0.9460 | |
| SUM225CWN | HER2amp | Basal A | Triciribine | AKT | AKT | 0.267 | uM | 7534.074 | 0.6945 | 0.4369 | 1.1026 | |
| AU565 | HER2amp | Luminal | GSK1838705A | IGF1R | RTK | 2.67 | uM | 5900.098 | 0.2633 | 0.1179 | 2.2937 | |
| BT-474 | HER2amp | Luminal | Mebendazole | 0.00427 | uM | 13125.174 | 0.9509 | 0.8986 | 0.9685 | |||
| UACC-812 | HER2amp | Luminal | ICRF-193 | TOP2 | TOP | 0.000427 | uM | 10580.139 | 0.8983 | 0.7855 | 0.9460 | |
| SK-BR-3 | HER2amp | Luminal | Triciribine | AKT | AKT | 33.3 | uM | 7527.074 | 0.1127 | -0.3600 | 1.9162 | |
| AU565 | HER2amp | Luminal | GSK1838705A | IGF1R | RTK | 13.3 | uM | 5900.098 | 0.0153 | -0.6767 | 2.2937 | |
| AU565 | HER2amp | Luminal | Mebendazole | 13.3 | uM | 13030.174 | 0.5128 | -0.0788 | 0.8615 | |||
| UACC-812 | HER2amp | Luminal | ICRF-193 | TOP2 | TOP | 0.00213 | uM | 10580.139 | 0.9382 | 0.8697 | 0.9460 | |
| SK-BR-3 | HER2amp | Luminal | Triciribine | AKT | AKT | 0.0000853 | uM | 7527.074 | 0.9623 | 0.9603 | 1.9162 | |
| AU565 | HER2amp | Luminal | GSK1838705A | IGF1R | RTK | 66.7 | uM | 5900.098 | 0.0045 | -0.8099 | 2.2937 | |
| BT-474 | HER2amp | Luminal | Mebendazole | 2.67 | uM | 13125.174 | 0.5156 | 0.0091 | 0.9685 | |||
| UACC-812 | HER2amp | Luminal | ICRF-193 | TOP2 | TOP | 0.000128 | uM | 11938.157 | 0.8114 | 0.4835 | 0.6995 | |
| SK-BR-3 | HER2amp | Luminal | Triciribine | AKT | AKT | 6.67 | uM | 7526.074 | 0.0972 | -0.5129 | 1.6506 | |
| AU565 | HER2amp | Luminal | GSK1838705A | IGF1R | RTK | 0.000171 | uM | 5901.07 | 1.0060 | 1.0062 | 1.9178 | |
| BT-474 | HER2amp | Luminal | Mebendazole | 0.107 | uM | 13125.174 | 0.9145 | 0.8237 | 0.9685 | |||
| UACC-812 | HER2amp | Luminal | ICRF-193 | TOP2 | TOP | 0.00213 | uM | 10754.151 | 0.9994 | 0.9988 | 0.9579 | |
| SK-BR-3 | HER2amp | Luminal | Triciribine | AKT | AKT | 33.3 | uM | 7526.074 | 0.0893 | -0.5372 | 1.6506 | |
| AU565 | HER2amp | Luminal | GSK1838705A | IGF1R | RTK | 0.000853 | uM | 5901.07 | 0.9898 | 0.9893 | 1.9178 | |
| BT-474 | HER2amp | Luminal | Mebendazole | 0.533 | uM | 13125.174 | 0.5998 | 0.1798 | 0.9685 |